Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

490.28 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
Via The Motley Fool
Topics Economy
Exposures Economy
Market Monitor News June 02 (Ulta Beauty, ZScaler UP - GAP, Regeneron DOWN)
US stocks ended May cautiously after strong monthly gains, as renewed trade tensions with China stirred market uncertainty. 
Via Chartmill
Topics World Trade
Exposures Tariff
Temu Parent PDD, Regeneron Pharmaceutical And Burlington Stores Are Among Top 11 Large-Cap Losers Last Week (May 26-May 30): Are The Others In Your Portfolio?
11 large-cap stocks with worst performance in last week: SMMT, PDD, REGN, BAH, OKTA, DECK, CPRT, COO, TPL, HPQ, BURL. Mixed results, lowered forecasts. 
Via Benzinga
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Forecasting The Future: 21 Analyst Projections For Regeneron Pharmaceuticals
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity For May 30
Via Benzinga
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Top S&P500 movers in Friday's session
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
Let's have a look at the S&P500 stocks with an unusual volume in today's session. 
Via Chartmill
Why Regeneron (REGN) Shares Are Falling Today
Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for Chronic... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Discover which S&P500 stocks are making waves on Friday.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session. 
Via Chartmill
Unity Stock Jumps On Upgrade While Regeneron, Cooper Companies Tank On Downgrades – Top Wall Street Analyst Calls Today
Jefferies upgraded Unity’s stock to ‘Buy’ from ‘Hold’ with a price target hike to $29 from $22. 
Via Stocktwits
Topics ETFs Economy Stocks
Exposures Economy Tariff US Equities
Friday's session: gap up and gap down stock in the S&P500 index
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Friday. Stay informed about the latest market trends. 
Via Chartmill
Traders are paying attention to the gapping stocks in Friday's session.
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Elastic, Gap, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Regeneron Pharmaceuticals Crashes 12% On A Surprise Sanofi-Tied Failure
Regeneron stock crashed Friday after the company's Sanofi-partnered COPD treatment unexpectedly failed in a Phase 3 study. 
Via Investor's Business Daily
These S&P500 stocks are moving in today's pre-market session
Pre-market stock analysis of S&P500 stocks on 2025-05-30: top gainers and losers in today's session. 
Via Chartmill
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal. 
Via Benzinga
Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Regeneron Stock Drops On Mixed Results For Smoker’s Lung Treatment
Both trials were conducted during the COVID-19 pandemic, a factor the companies said may have influenced the outcomes. 
Via Stocktwits
Topics Government Stocks
Exposures COVID-19 Political US Equities
2 Large-Cap Stocks to Target This Week and 1 to Keep Off Your Radar
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an... 
Via StockStory
The Company Buying 23andMe Is a Pharmaceutical Giant. Here's How Investors Can Benefit From the Move.
Via The Motley Fool
Topics Artificial Intelligence Bankruptcy
Exposures Artificial Intelligence Financial Legal
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Value Stocks with Questionable Fundamentals
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
Does the 23andMe Acquisition Make Regeneron a Buy Now?
Via The Motley Fool
Topics Bankruptcy
Exposures Financial Legal
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Via Benzinga
3 Cash-Producing Stocks in Hot Water
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
What's going on in today's session: S&P500 movers
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
Regeneron (REGN) to acquire 23andMe for $256 million, plans to maintain consumer services and uphold privacy policies. Deal expected to close Q3 2025. 
Via Benzinga
Regeneron To Buy Assets Of 23andMe For $256M: Retail Says ‘Fantastic’ For Future R&D Efforts
Upon closing of the deal, 23andMe will be operated as a wholly owned direct or indirect unit of Regeneron and will continue operations as a personal genomics service. 
Via Stocktwits
Topics Artificial Intelligence Bankruptcy
Exposures Artificial Intelligence Financial Legal
< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.